Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Oncotelic Therapeutics Inc
(OP:
OTLC
)
0.0778
UNCHANGED
Streaming Delayed Price
Updated: 3:57 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Oncotelic Therapeutics Inc
< Previous
1
2
3
Next >
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Three Accepted Abstracts on Deciparticle (TM) Everolimus (Sapu003) at 2025 San Antonio Breast Cancer Symposium
October 23, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Nanomedicine’s Next Leap: Why Particle Size Matters in Cancer Drug Delivery
October 21, 2025
Via
Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Positioned to Fill Critical Gaps in Cancer Care with RNA and Small-Molecule Therapies
October 17, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability
October 08, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Phase 1 Trial of Sapu-003, a Novel Intravenous Deciparticle(TM) Everolimus, Now Open for Enrollment in Australia
October 08, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium
October 08, 2025
Using Sapu Nano’s proprietary Deciparticle™ technology, Sapu-003 delivers everolimus intravenously
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval to Begin Human Clinical Trials of Sapu003, an Injectible Form of Afinitor(R) (Everolimus) for Breast Cancer Treatment
October 01, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Joint Venture Sapu Nano Receives Approval to Begin Phase 1 Trial of Injectable Everolimus for Breast Cancer
September 24, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
September 24, 2025
Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, by Delivering Full Strength of the Drug via Intravenous Injection
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) CEO Featured on IBN’s BioMedWire Podcast
September 22, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Oncotelic Therapeutics Inc. (OTLC): Leadership and Innovation Drive Late-Stage Biotech Momentum
September 19, 2025
Via
Investor Brand Network
Topics
Intellectual Property
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Release on Innovative Therapeutics Pipeline
September 19, 2025
Via
Investor Brand Network
Topics
Intellectual Property
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Advancing Cancer Research
September 18, 2025
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating Pioneering Pipeline Designed to Transform Cancer, Rare Diseases Treatments
September 18, 2025
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Advancing Cancer Research Brings New Hope for Patients Worldwide
September 17, 2025
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Oncotelic Therapeutics Inc. (OTLC) Champions Targeted RNA Therapy for Underserved Cancers
September 17, 2025
Via
Investor Brand Network
Topics
Death
Advancing Cancer Research Brings New Hope for Patients Worldwide
September 17, 2025
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Intellectual Property
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial Highlighting Innovative Therapeutics Pipeline
September 16, 2025
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments
September 16, 2025
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
September 15, 2025
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
September 15, 2025
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NASDAQ:SRPT),(NASDAQ:AUTL),(NASDAQ:ARCT) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights Two Years of Clinical Milestones Across Oncology and Rare Disease Programs
September 12, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline
September 12, 2025
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Engages IBN to Lead Corporate Communications
September 10, 2025
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights CEO Dr. Vuong Trieu’s Impact and Clinical Pipeline Progress
September 04, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics’ Commitment to Innovation, Life-Saving Therapies
September 04, 2025
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Therapeutics Inc. (OTLC) Is ‘One to Watch’
September 03, 2025
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Showcases Pipeline and CEO’s Intellectual Property Legacy
August 28, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets
May 29, 2024
Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets
Via
News Direct
OTCQB Venture Virtual Investor Conference Agenda Announced for August 7th
August 04, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.